Apixaban for Extended Treatment of Provoked VTE: New NEJM Study Challenges Treatment Paradigm
Emma P. with Clinical Research Professionals shared a post on LinkedIn:
“Apixaban for Extended Treatment of Provoked Venous Thromboembolism
A recent publication in The New England Journal of Medicine explores the benefits of continuing anticoagulation therapy with apixaban in patients who experienced venous thromboembolism (VTE) due to transient provoking factors like surgery, trauma, or immobility. Traditionally, these patients receive short-term anticoagulation, but this study challenges that paradigm.
Title: Apixaban for Extended Treatment of Provoked Venous Thromboembolism
Authors: Gregory Piazza, Behnood Bikdeli, Arvind K. Pandey, Darsiya Krishnathasan, Candrika D. Khairani, Antoine Bejjani, Ruth H. Morrison, Heather Hogan, Sina Rashedi, Mariana Pfeferman, Junyang Lou, John Fanikos, Nicole Porio, Lisa Rosenbaum, Piotr Sobieszczyk, Zhou Lan, Marie Gerhard-Herman, Umberto Campia, Samuel Z. Goldhaber
* Study Design:
Researchers conducted a randomized, double-blind trial comparing extended apixaban therapy to placebo in patients with provoked VTE who had completed initial anticoagulation. The goal: assess whether continued treatment could prevent recurrence without increasing bleeding risk.
* Key Findings:
• Apixaban reduced recurrent VTE by 82% compared to placebo.
• Major bleeding rates were low and comparable between groups.
• The benefit was consistent across subgroups, including those with persistent risk factors like obesity or cancer history.
* Clinical Implications:
This study suggests that extended apixaban therapy may be appropriate for select patients with provoked VTE, especially when enduring risk factors exist. It calls for a more individualized approach to anticoagulation duration—balancing recurrence risk with bleeding concerns.
* Why It Matters:
VTE remains a leading cause of preventable hospital death. This research could reshape guidelines and improve long-term outcomes for thousands of patients annually.
For clinicians, researchers, and policy-makers: this is a pivotal moment to re-evaluate how we define “provoked” VTE and tailor treatment accordingly.
Clinical and Research Focus
Broader Impact and Engagement.”
Stay updated with Hemostasis Today.
-
Aug 29, 2026, 11:03Richard Davis: Navigating Acute PE – ESC vs. the New AHA/ACC Guidelines
-
Aug 29, 2026, 10:57Bartosz Hudzik: First RCT Evidence for a Long-Standing Guideline Gray Zone
-
Aug 29, 2026, 10:50Edward Lee Carter: Breakthrough Stroke Beyond ‘DOAC Failure’ – Risk Stratification Insights from ASPERA-R
-
Aug 29, 2026, 10:45Amir Askarinejad: SINGLE-AF at ESC 2026 – Important New Data for Anticoagulation in Intermediate-Risk AF
-
Aug 29, 2026, 10:26Paulus Kirchhof: Anticoagulation in Patients with a Single CHADS-VA Risk Factor
-
Aug 29, 2026, 10:22Syed Zohad Shah: Reducing Blood Loss and Hospital Stays in Non-Cardiac Thoracic Surgery
-
Aug 29, 2026, 10:13Eric Alderman: A New FDA-Approved Treatment for Warm Autoimmune Hemolytic Anemia
-
Aug 29, 2026, 09:10Ageing with a Bleeding Disorder Podcast – European Haemophilia Consortium
-
Aug 29, 2026, 09:04Abdul Muqtadir Abbasi: Perioperative Anticoagulation Management Chart